> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Sets May 1, 2027 Decision Date For uniQure's Huntington's Gene Therapy
- URL: https://www.bullished.co/fda-sets-may-1-2027-decision-date-for-uniqures-huntingtons-gene-therapy-5c1252cc/
- Published: 2026-11-02T12:21:06.000Z
- Updated: 2026-11-02T12:21:06.000Z
- Description: The agency granted Priority Review to ifezuntirgene inilparvovec and tentatively plans an advisory committee meeting, uniQure said.
- Author: Matteo Parrino
- Tags: SEC Filings, QURE, Industry: Healthcare

[uniQure](https://www.bullished.co/tag/qure/), which develops one-time gene therapies for rare and serious diseases, said the FDA accepted its application for the Huntington's disease treatment ifezuntirgene inilparvovec and set a [May 1, 2027 target action date](https://www.sec.gov/Archives/edgar/data/0001590560/000110465926120915/tm2628699d1%5F8k.htm?ref=bullished.co), according to an [8-K](https://www.bullished.co/learn/8-k-items-explained/) filed Monday. The application, submitted under the Accelerated Approval pathway, received Priority Review.

## Review timetable and advisory panel

The May 1, 2027 date is a target under the Prescription Drug User Fee Act, the law that sets FDA review deadlines. In its acceptance letter, the FDA said it is tentatively planning to discuss the application at an Advisory Committee meeting, and uniQure will be notified once the date and timelines are finalized.

The application rests on the previously announced 36-month analysis of the Phase I/II study, which was compared against a propensity score-matched external control drawn from the Enroll-HD natural history database. uniQure announced that analysis on September 24, 2025.

The therapy is the first investigational Huntington's treatment to receive both Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations from the FDA, the company said. It also holds Fast Track designation.

## A 200-patient confirmatory trial

uniQure and the FDA have aligned on key elements of a confirmatory study. It is a randomized trial of about 200 patients, split 2:1 between the gene therapy and standard of care, with Total Functional Capacity at 36 months as the main goal.

The company plans to begin U.S. patient screening by the end of 2026\. CEO Matt Kapusta said the trial is expected to be "well underway by the time of potential approval."

The [press release](https://www.sec.gov/Archives/edgar/data/0001590560/000110465926120915/tm2628699d1%5Fex99-1.htm?ref=bullished.co) says the Phase I/II studies have dosed 51 patients in total. Patients receive a single treatment delivered by MRI-guided neurosurgery into the striatum, a brain region.

## What uniQure is selling

The therapy uses uniQure's gene-silencing miQURE platform, designed to silence the huntingtin gene. The company's other candidates target refractory mesial temporal lobe epilepsy, Fabry disease and SOD1 amyotrophic lethal sclerosis, and it has the hemophilia B therapy HEMGENIX, for which CSL Behring holds global rights.

The company's risk language flags that the FDA could conclude the Phase I/II or confirmatory data do not support accelerated approval. Approval, if granted, could also carry post-approval requirements that are difficult or costly to meet.

uniQure [reports third-quarter results](https://finance.yahoo.com/healthcare/articles/uniqure-announce-third-quarter-2026-110500332.html?ref=bullished.co) before the market opens Wednesday, November 4, with a call at 8:30 a.m. ET.

Learn

- [Item 7.01: Regulation FD disclosure →](https://www.bullished.co/learn/8-k-items-explained/#item-701-regulation-fd-disclosure)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — uniQure N.V. (QURE)](https://www.sec.gov/Archives/edgar/data/0001590560/000110465926120915/tm2628699d1%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tm2628699d1\_ex99-1.htm — uniQure N.V. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001590560/000110465926120915/tm2628699d1%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR
- [uniQure to Announce Third Quarter 2026 Financial Results](https://finance.yahoo.com/healthcare/articles/uniqure-announce-third-quarter-2026-110500332.html?ref=bullished.co) — Yahoo Finance

### More on uniQure

- [UniQure's Huntington's Gene Therapy Shows 44% Disease Slowing At Four Years, Missing Its Primary Endpoint](https://www.bullished.co/uniqures-huntingtons-gene-therapy-shows-44-disease-slowing-at-four-years-missing-its-204be3a6/)

[All uniQure (QURE) coverage →](https://www.bullished.co/tag/qure/)